{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Blood Podcast","title":"Prospective Study for VTE and a Phase II Study on Sapablursen","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/4dce44e2\"></iframe>","width":"100%","height":180,"duration":882,"description":"In this week's episode, Blood editor Dr. Laura Michaelis interviews Dr. Sabine Eichinger of the Medical University of Vienna, and Dr. Jeanne Palmer of the Mayo Clinic on their latest articles published in Blood highlighting emerging research and treatment strategies in hematology. Dr. Eichinger discusses a prospective study examining the risk of recurrent venous thromboembolism (VTE) in patients with provoked thrombosis, revealing that recurrence rates were higher than previously estimated, particularly among patients with major transient risk factors. Her findings suggest that recurrence risk is not uniform and that anticoagulation duration should be individualized rather than based on a one-size-fits-all approach. Dr. Jeanne Palmer then reviews a Phase II clinical trial of sapablursin, a novel hepcidin mimetic for polycythemia vera, explaining how the agent regulates iron availability to reduce erythropoiesis, decrease phlebotomy requirements, and potentially improve patients' quality of life.\nFeatured Articles: \nRisk of recurrence in patients with provoked venous thromboembolism: a prospective cohort study\nSapablursen for erythrocytosis control in patients with polycythemia vera","thumbnail_url":"https://img.transistorcdn.com/v7MGyoJEM-ebFBYi5VpSwDRF3QY3zbinfCyyOAH1TGk/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9kY2Q4/YzJhZmMwODBjOWRi/YTNhN2Y1NWJkMzMw/NTBjZi5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}